Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.76 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.76 |
| ▸ | AKT1 | P31749 | 2/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.60 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.59 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | SI | P14410 | 2/20 | 0.58 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954625 | 1.00 | ALOX5 (1.00) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL29928945 | 1.00 | ALOX5 (1.00) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL20045161 | 0.95 | ALOX5 (0.90) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL20045168 | 0.95 | ALOX5 (0.90) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL16769856 | 0.92 | PTGES (0.84) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL29359086 | 0.92 | PTGES (0.84) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL26621012 | 0.88 | ALOX5 (0.79) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL3336163 | 0.87 | ALOX5 (0.77) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL3336171 | 0.87 | ALOX5 (0.77) | ALOX5PTGESDYRK1ADYRK1BAKT1 | |
| SCHEMBL29833892 | 0.87 | ALOX5 (0.77) | ALOX5PTGESDYRK1ADYRK1BAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 554 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20250381166-A1 | Cannabis-Derived Flavonoids And Related Methods | CANURTA INC (CA) | 2025-12-18 | — | — | US | claimed |
| WO-2025227265-A1 | METHODS FOR CONCENTRATING POLYPHENOLIC COMPOUNDS | CANURTA INC. (CA) | 2025-11-06 | — | — | WO | claimed |
| US-12453753-B2 | Oxygenated cannabis skin therapy compositions and methods for producing the compositions | Pauwels, David (US) | 2025-10-28 | — | — | US | claimed |
| US-12440528-B2 | Methods of treating ovarian cancer with hemp extract | Ecofibre USA Inc. (US) | 2025-10-14 | — | — | US | claimed |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2025-09-11 | — | — | US | claimed |
| EP-4281046-B1 | NALTREXONE COMPOSITIONS | LDN PHARMA LTD (GB) | 2025-09-10 | — | — | EP | claimed |
| EP-4608425-A1 | METHODS OF TREATING ESTROGEN SENSITIVE DISEASES WITH CANNABIS EXTRACT | Ecofibre USA Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| EP-4595958-A1 | CANNABIS COMPOSITIONS ENRICHED WITH CBCA/CBC FOR CONSISTENT PAIN RELIEF | Panaxia Pharmaceutical Industries Ltd. (IL) | 2025-08-06 | — | — | EP | claimed |
| EP-4223749-B1 | PREPARATION METHOD FOR CANNFLAVIN COMPOUNDS | DEYI PHARMACEUTICAL LTD (CN) | 2025-08-06 | — | — | EP | claimed |
| US-11331300-B2 | Reversing baldness through follicle regeneration | POSTREL RICHARD (US) | 2022-05-17 | — | — | US | claimed |
| US-20220142942-A1 | CANNABINOID POUCHES | TRINIDAD CONSULTING, LLC (US) | 2022-05-12 | — | — | US | claimed |
| WO-2022074541-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES | Max Biology Co. Ltd. (KH) | 2022-04-14 | — | — | WO | claimed |
| WO-2022064203-A1 | PACKAGED FORMULATION | Nicoventures Trading Limited (GB) | 2022-03-31 | — | — | WO | claimed |
| WO-2022067143-A1 | ORAL CARE COMPOSITIONS COMPRISING PRENYLATED FLAVONOIDS | THE PROCTER & GAMBLE COMPANY (US) | 2022-03-31 | — | — | WO | claimed |
| US-20220096364-A1 | Oral Care Compositions Comprising Prenylated Flavonoid | THE PROCTER & GAMBLE COMPANY | 2022-03-31 | — | — | US | claimed |
| WO-2022064204-A1 | FORMULATION | Nicoventures Trading Limited (GB) | 2022-03-31 | — | — | WO | claimed |
| US-20220079916-A1 | USE OF GERANYLFLAVONE A IN PREPARATION OF DRUG FOR PROMOTING HEALING OF WOUNDS | HANYI BIO-TECHNOLOGY COMPANY LTD. (CN) | 2022-03-17 | — | — | US | claimed |
| WO-2022047016-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS | CREDO SCIENCE, LLC (US) | 2022-03-03 | — | — | WO | claimed |
| US-11261477-B2 | Glycosylation modification of bioactive compounds and drugs by plant glycosyltransferases (UGTs) | UNIVERSITY OF NORTH TEXAS (US) | 2022-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079916-A1 | USE OF GERANYLFLAVONE A IN PREPARATION OF DRUG FOR PROMOTING HEALING OF WOUNDS | AGER, GID4, MFN2 | ALOX5 72/4885PTGES 258/4885DYRK1A 2816/4885 |
| US-20250281481-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILTY OF 5-HT RECEPTOR AGONISTS | VDR, OPRD1, HTR1A | ALOX5 754/4885PTGES 1654/4885DYRK1A 1155/4885 |
| US-12453753-B2 | Oxygenated cannabis skin therapy compositions and methods for producing the compositions | CNR2, OXER1, CNR1 | ALOX5 17/4885PTGES 193/4885DYRK1A 2483/4885 |
| US-20220096364-A1 | Oral Care Compositions Comprising Prenylated Flavonoid | PROC, F9, SP1 | ALOX5 4179/4885PTGES 4122/4885DYRK1A 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.